IRVINE, Calif. and PLAINSBORO, N.J., Aug. 28, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) and the University Medical Center of Princeton at Plainsboro, N.J. (UMCPP), announced today the successful installation of Masimo Patient SafetyNet™, clinically shown to reduce rapid response activations, intensive care unit (ICU) transfers, and deaths related to opioid-induced respiratory depression, while offering significant cost savings opportunity.
UMCPP joins a growing list of distinguished hospitals using Masimo Patient SafetyNet, which tracks the underlying physiological conditions of patients, and detects changes and abnormalities that signal declining health status in real time. When a patient's condition deteriorates, the system automatically sends wireless alerts directly to clinicians – prompting a potentially lifesaving response to the patient's bedside. The Masimo Patient SafetyNet system consists of Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, choice of patient-tolerant and easy-to-use ventilation monitoring with rainbow® Acoustic Monitoring or standard capnography, and remote monitoring and notification to keep clinicians connected to patients.
This year the clinical care provided by UMCPP received an "A" in patient safety from The Leapfrog Group, an independent, national nonprofit working to improve the safety, quality, and affordability of healthcare. More than 2,600 hospitals were evaluated – only about one-fourth of those earned an "A."
"We are committed to patient safety and incorporating new technologies and practices that will ensure that we continue to be considered among the safest hospitals in the nation," said Linda F. Sieglen, MD, MMM, a board certified anesthesiologist and Senior Vice President of Medical Affairs for Princeton HealthCare System, which includes UMCPP.
Improved care does not need to come at a higher cost. Clinicians at Dartmouth Hitchcock Medical Center, for instance, reported that using Patient SafetyNet on just one floor reduced ICU transfers and created an annual opportunity-cost savings of $1.48 million(1).
Michael O'Reilly, MD, Chief Medical Officer of Masimo, stated: "We are excited to join UMCPP in its mission to provide safe, cost-efficient care, and to help offer its patients and their families peace of mind. With Masimo technologies on the general floor, clinicians can be confident their patients are being watched even when they aren't at the bedside, while families can be assured their loved ones are safe."
(1) Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J. "Postoperative Monitoring – The Dartmouth Experience." Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online
About University Medical Center of Princeton at Plainsboro
A unit of Princeton HealthCare System, University Medical Center of Princeton at Plainsboro opened in May 2012 as the hub of a 171-acre health campus in Plainsboro, N.J. UMCPP is a University Hospital Affiliate of the University of Medicine & Dentistry of New Jersey—Robert Wood Johnson Medical School, a Clinical Research Affiliate of The Cancer Institute of New Jersey, an accredited oncology-teaching program of the American College of Surgeons' Commission on Cancer (CoC) and recipient of the CoC's Outstanding Achievement Award. Through a partnership with The Children's Hospital of Philadelphia (CHOP), UMCPP offers enhanced pediatric services, with CHOP physicians working onsite to provide pediatric emergency consultation, inpatient pediatric care and neonatal care. Visit www.princetonhcs.org
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®), PVI®, acoustic respiration rate (RRa™), and SEDLine® contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.